Literature DB >> 21414250

Blockade of dopamine D₃ but not D₂ receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment.

David J G Watson1, Charles A Marsden, Mark J Millan, Kevin C F Fone.   

Abstract

Dopamine D₃ receptors are densely expressed in mesolimbic projection areas, and selective antagonists enhance cognition, consistent with their potential therapeutic use in the treatment of schizophrenia. This study examines the effect of dopamine D₃ vs. D₂ receptor antagonists on the cognitive impairment and hyperactivity produced by social isolation of rat pups, in a neurodevelopmental model of certain deficits of schizophrenia. Three separate groups of male Lister hooded rats were group-housed or isolation-reared from weaning. Six weeks later rats received either vehicle or the dopamine D₃ selective antagonist, S33084 (0.04 and 0.16 mg/kg), the preferential D₃ antagonist, S33138 (0.16 and 0.63 mg/kg) or the preferential D₂ antagonist, L-741,626 (0.63 mg/kg) s.c. 30 min prior to recording; horizontal locomotor activity in a novel arena for 60 min and, the following day, novel object discrimination using a 2-h inter-trial interval. Isolation rearing induced locomotor hyperactivity in a novel arena and impaired novel object discrimination compared to that in group-housed littermates. Both S33084 and S33138 restored novel object discrimination deficits in isolation-reared rats without affecting discrimination in group-housed controls. By contrast, L-741,626 impaired novel object discrimination in group-housed rats, without affecting impairment in isolates. S33084 (0.16 mg/kg), S33138 and, less markedly, L741,626 reduced the locomotor hyperactivity in isolates without attenuating activity in group-housed controls. Selective blockade of dopamine D₃ receptors reverses the visual recognition memory deficit and hyperactivity produced by isolation rearing. These data support further investigation of the potential use of dopamine D₃ receptor antagonists to treat schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21414250     DOI: 10.1017/S1461145711000435

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  33 in total

1.  Neonatal phencyclidine administration and post-weaning social isolation as a dual-hit model of 'schizophrenia-like' behaviour in the rat.

Authors:  Philip L R Gaskin; Stephen P H Alexander; Kevin C F Fone
Journal:  Psychopharmacology (Berl)       Date:  2014-01-09       Impact factor: 4.530

Review 2.  Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders.

Authors:  Christian Heidbreder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-10-28       Impact factor: 3.000

3.  Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: the complex mechanism of blonanserin action involving D₃-5-HT₂A and D₁-NMDA receptors in the mPFC.

Authors:  Hirotake Hida; Akihiro Mouri; Kentaro Mori; Yurie Matsumoto; Takeshi Seki; Masayuki Taniguchi; Kiyofumi Yamada; Kunihiro Iwamoto; Norio Ozaki; Toshitaka Nabeshima; Yukihiro Noda
Journal:  Neuropsychopharmacology       Date:  2014-08-14       Impact factor: 7.853

Review 4.  Animal models of schizophrenia.

Authors:  C A Jones; D J G Watson; K C F Fone
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

5.  Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex.

Authors:  David J G Watson; Florence Loiseau; Manuela Ingallinesi; Mark J Millan; Charles A Marsden; Kevin C F Fone
Journal:  Neuropsychopharmacology       Date:  2011-10-26       Impact factor: 7.853

Review 6.  The potential role of dopamine D₃ receptor neurotransmission in cognition.

Authors:  Shinichiro Nakajima; Philip Gerretsen; Hiroyoshi Takeuchi; Fernando Caravaggio; Tiffany Chow; Bernard Le Foll; Benoit Mulsant; Bruce Pollock; Ariel Graff-Guerrero
Journal:  Eur Neuropsychopharmacol       Date:  2013-06-20       Impact factor: 4.600

7.  Disrupted-in-schizophrenia-1 Gln31Leu polymorphism results in social anhedonia associated with monoaminergic imbalance and reduction of CREB and β-arrestin-1,2 in the nucleus accumbens in a mouse model of depression.

Authors:  Tatiana V Lipina; Paul J Fletcher; Frankie H Lee; Albert H C Wong; John C Roder
Journal:  Neuropsychopharmacology       Date:  2012-09-26       Impact factor: 7.853

8.  Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse.

Authors:  Ross Zimnisky; Gloria Chang; István Gyertyán; Béla Kiss; Nika Adham; Claudia Schmauss
Journal:  Psychopharmacology (Berl)       Date:  2012-10-19       Impact factor: 4.530

9.  Dopamine D3 receptors in the basolateral amygdala and the lateral habenula modulate cue-induced reinstatement of nicotine seeking.

Authors:  Maram A T M Khaled; Abhiram Pushparaj; Patricia Di Ciano; Jorge Diaz; Bernard Le Foll
Journal:  Neuropsychopharmacology       Date:  2014-07-07       Impact factor: 7.853

10.  Differential effects of cathinone compounds and MDMA on body temperature in the rat, and pharmacological characterization of mephedrone-induced hypothermia.

Authors:  S E Shortall; A R Green; K M Swift; K C F Fone; M V King
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.